Aadi Bioscience to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Aadi Bioscience, Inc. (NASDAQ: AADI) announces participation in investor events: H.C. Wainwright 25th Annual Global Investment Conference and Morgan Stanley 21st Annual Global Healthcare Conference. CEO and CFO will present and participate in fireside chat respectively.

Positive

• Investor events provide opportunities for Aadi Bioscience to showcase its precision therapies for genetically defined cancers with mTOR pathway alterations, potentially attracting investors and boosting stock price.

Negative

• None.

LOS ANGELES, Sept. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with mTOR pathway alterations, announced today participation at the following investor events:

• H.C. Wainwright 25^th Annual Global Investment Conference - The conference will take place September 11-13, 2023, in both a virtual and in-person format in New York City.  Scott Giacobello, Interim CEO and President and CFO of Aadi, will present in-person on Tuesday, September 12, 2023, at 12:00 pm ET. 
• Morgan Stanley 21^st Annual Global Healthcare Conference – The conference will take place September 11-13, 2023, in New York City.  Mr. Giacobello will participate in an in-person fireside chat on Wednesday, September 13, 2023, at 9:30 am ET. 

The presentation and fireside chat will be webcast live on the IR pages of the Aadi Bioscience website and will be available for replay for approximately 30 days following each investor event.

About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval in November 2021, and in February 2022 commenced commercialization of FYARRO^® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi is conducting the PRECISION1 trial, a Phase 2 tumor-agnostic registration-directed study in patients with mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on Aadi's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
Marcy Graham
IR@aadibio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-participate-at-upcoming-investor-conferences-301917694.html

SOURCE Aadi Bioscience

FAQ

What investor events is Aadi Bioscience participating in?

Aadi Bioscience is participating in the H.C. Wainwright 25th Annual Global Investment Conference and the Morgan Stanley 21st Annual Global Healthcare Conference.

Who will be presenting at the H.C. Wainwright conference?

Scott Giacobello, Interim CEO and President, and CFO of Aadi Bioscience will be presenting at the H.C. Wainwright conference.

Where can I watch the presentations and fireside chat?

The presentations and fireside chat will be webcast live on the IR pages of the Aadi Bioscience website.

How long will the replays be available?

The replays will be available for approximately 30 days following each investor event.